Epilepsy, which afflicts approximately 4.7 million people in the G7 according to DRGepidemiology, is a heterogeneous condition requiring individualized treatment based largely on a patient’s seizure syndrome and seizure type. The epilepsy market is highly generic, although some branded third-generation antiepileptic drugs (AEDs) have garnered notable patient share. While a few sponsors continue to follow the traditional path for drug approval in epilepsy, most drug developers are targeting underserved, orphan pediatric epilepsy indications or are developing novel formulations of rescue therapies for acute repetitive seizures. Understanding the trajectory of this established but evolving market and the niche opportunities therein is key for marketers of both current and emerging brands.
Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.
Primary research: Approximately 20 country-specific interviews with thought-leading neurologists; supported by survey data collected for this and other DRG research.
Epidemiology: Diagnosed prevalence of epilepsy by country, segmented by generalized and partial-onset seizures; drug-treated cases.
Emerging therapies: Phase II: 10 drugs; Phase III: 6 drugs; preregistration: 2 drugs; registered: 38 drugs. Coverage of 11 select preclinical and Phase I products.
Market forecast features: Patient-based market forecast extending through 2027.
Key companies: Aquestive Therapeutics, Eisai, GlaxoSmithKline, GW Pharmaceuticals, Insys Therapeutics, Lundbeck, Marinus Pharmaceuticals, Neurelis, Pfizer, Sanofi, SK Biopharmaceuticals, Sunovion, Supernus, UCB, Upsher-Smith, Zogenix.
Key drugs: levetiracetam, lamotrigine, carbamazepine, valproates, Vimpat (lacosamide), Aptiom/Zebinix (eslicarbazepine acetate), Fycompa (perampanel), Briviact (brivaracetam), AQST-120 (clobazam oral film), Epidiolex (plant-derived CBD), synthetic CBD, ZX-008 (fenfluramine), YKP-3089 (cenobamate), AQST-203 (buccal diazepam), NRL-1 (intranasal diazepam), USL-261 (intranasal midazolam).